Citations

Mayo Clinic

Showing 10 of 108599 citations.

Coexistence of multiple sclerosis and spinocerebellar ataxia type-8
Neyal, Nur , Keegan, B. Mark , Kantarci, Orhun H. , Zeydan, Burcu , Keegan, B Mark , Zeydan, Burcu

Multiple Sclerosis Journal | July 4, 2023 | Volume: 29 | Issue: 9 | Pages: 1195-1198

10.1177/13524585231180549 | PMID 37401111 Get It

Cerebellar dysfunction is likely to cause severe and treatment-resistant disability in multiple sclerosis (MS). Certain spinocerebellar ataxia (SCA)-related alleles can increase MS susceptibility, and channel polymorphisms can impact disability measures. Following an index patient with the coexistence of MS and SCA Type-8 (SCA8) in the MS clinic, an institutional engine search for MS and hereditary ataxia coexistence was conducted but did not reveal any other cases. This extremely rare coexistence of MS and SCA8 in our index patient may be incidental; however, a yet-to-be-identified contribution of coexistent hereditary ataxia(s) to the susceptibility of a prominent progressive ataxia MS phenotype cannot be ruled out.
Association of the CHEK2 c. 1100delC variant, radiotherapy, and systemic treatment with contralateral b
Morra, Anna , Schreurs, Maartje A. C. , Andrulis, Irene L. , Anton‐Culver, Hoda , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Dörk, Thilo , Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Graßmann, Felix , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Hopper, John L. , Houlston, Richard S. , Howell, Anthony, Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, John, Esther M. , Johnson, Nichola , Jones, Michael E. , Kristensen, Vessela N. , Kurian, Allison W. , Lambrechts, Diether , Lindblom, Annika , Mannermaa, Arto, Mavroudis, Dimitrios, Muranen, Taru , Nevelsteen, Ines, Neven, Patrick , Newman, William G. , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Peterlongo, Paolo , Phillips, Kelly‐Anne , Plaseska‐Karanfilska, Dijana , Rack, Brigitte , Rhenius, Valerie , Romero, Atocha , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Pharoah, Paul D.P. , Adank, Muriel A. , Hooning, Maartje J. , Howell, Anthony , Ramus, Susan J. , Bojesen, Stig E. , Eccles, Diana , Cummings, Margaret C. , Loi, Sherene , Lambrechts, Diether , Howell, Sacha J. , Bojesen, Stig E , Dörk, Thilo , Figueroa, Jonine D , Gabrielson, Marike , Gago-Dominguez, Manuela , García-Sáenz, José A , Hahnen, Eric , Hartikainen, Jaana M , Jernström, Helena , John, Esther M , Lambrechts, Diether , Muranen, Taru A , Nevanlinna, H , Patel, Alpa V , Pylkäs, Katri , Rashid, Muhammad U , Hooning, Maartje J. , Lambrechts, Diether , Peterlongo, Paolo , Ramus, Susan J , Pharoah, Paul D P , Eccles, Diana , Houlston, Richard S , Anton-Culver, Hoda , Evans, D Gareth , Jones, Michael E , Newman, William G , Romero, Atocha , García-Closas, Montserrat , Kurian, Allison W , Loi, Sherene , Bojesen, Stig E , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Augustinsson, Annelie , Behrens, Sabine , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Collaborators, NBCS, Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Daly, Mary Beryl , Dennis, Joe , Devilee, Peter , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Hartikainen, Jaana M. , Howell, Anthony, Investigators, ABCTB, Investigators, kConFab, Jakubowska, Anna , Jernström, Helena , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mannermaa, Arto, Mulligan, Anna Marie , Nevanlinna, Heli , Olshan, Andrew F. , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Saloustros, Emmanouil , Scott, Christopher G. , Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Hollestelle, Antoinette , Schmidt, Marjanka K.

Cancer Medicine | July 4, 2023 | Volume: 12 | Issue: 15 | Pages: 16142-16162

10.1002/cam4.6272 | PMID 37401034 Get It

Abstract Background Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC‐specific survival (BCSS) compared to non‐carriers. Aim To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Methods Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow‐up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi‐state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. Results There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi‐state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non‐carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09–1.56)]. Conclusion Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.
Clinical Predictors of C5 Spinal Nerve Viability in Pan−Brachial Plexus Injuries
Wu, Kitty Y. , Asserson, Derek B. , Loosbrock, Michelle F., Spinner, Robert J. , Bishop, Allen T. , Shin, Alexander Y.

Plastic & Reconstructive Surgery | July 4, 2023 | Volume: 153 | Issue: 6 | Pages: 1131e-1137e

10.1097/prs.0000000000010906 | PMID 37400947 Get It

Background: In pan–brachial plexus injury, distinguishing between preganglionic and postganglionic injuries is crucial to reconstructive planning. This study aimed to identify preoperative factors that would accurately predict a reconstructible C5 spinal nerve. Methods: Patients with pan–brachial plexus injury from a single institution between 2001 and 2018 were reviewed. Patient demographics, clinical examination, diagnostic imaging, and electrodiagnostic results were recorded. C5 viability was determined based on supraclavicular exploration and intraoperative electrophysiologic testing. Univariate analysis identified significant factors for regression analysis. A multivariable parsimonious model was created using stepwise high-performance logistic regression. Results: A total of 311 patients (mean age, 29.9 years; 46 women and 265 men; mean Injury Severity Score, 17.2) were included. A total of 134 patients (43%) had a viable C5 nerve, and 50 patients (12%) had a viable C6 nerve. Intact C5 spinal nerve on computed tomographic (CT) myelogram (OR, 5.4), positive Tinel test (OR, 2.6), muscle strength greater than or equal to 4 (according to the modified British Medical Research Council scale) for the rhomboid (OR, 1.3) or greater than or equal to 4 for the serratus anterior (OR, 1.4), and rhomboid needle electromyography (OR, 1.8) were predictive of having a viable C5 spinal nerve. The multivariable parsimonious stepwise model (area under the curve, 0.77) included four factors: positive Tinel test, intact C5 spinal nerve on CT myelogram, hemidiaphragmatic elevation, and midcervical paraspinal fibrillations. Conclusions: In this cohort of pan–brachial plexus patients with major polytrauma, there was a 43% incidence of viable C5 spinal nerve. A positive Tinel test (OR, 2.1) and intact C5 spinal nerve on CT myelogram (OR, 4.9) predicted a viable C5 nerve. In contrast, hemidiaphragmatic elevation (OR, 3.1) and midcervical paraspinal fibrillations (OR, 2.92) predicted root avulsion. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
Synthetic Tape Augmentation for Thumb Carpometacarpal Joint Instability: Surgical Technique
Townsley, Sarah, Kakar, Sanjeev , Kakar, Sanjeev

Journal of Wrist Surgery | July 3, 2023 | Volume: 13 | Issue: 04 | Pages: 356-361

10.1055/s-0043-1770789 | PMID 39027031 Get It

Abstract Background Dorsal thumb carpometacarpal (CMC) instability can occur after traumatic injury and can lead to persistent pain and dysfunction of the hand. We present a case report of a joint-sparing technique for recurrent thumb CMC instability after failed Eaton–Littler procedure. Case Description We describe a technique to repair the dorsal radial ligament and augment the repair with dorsal synthetic tape. To illustrate this technique, we describe a patient who underwent the synthetic tape augmentation procedure for recurrent thumb CMC instability after a failed Eaton–Littler reconstruction. Preoperative and postoperative grip strength, appositional pinch, oppositional pinch, radial abduction, palmar abduction, and postoperative quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) were recorded. At final follow-up 18 months after surgery, the patient had returned to manual work without any functional sequelae. The thumb CMC joint was stable and his postoperative QuickDASH score was 15.9. Literature Review Thumb CMC instability has traditionally been treated with Eaton–Littler ligament reconstruction which uses a slip of flexor carpi radialis tendon to reconstruct the deficient ligaments. More recently, the importance of the dorsal radial ligament in joint stability has been recognized and new procedures have been described to reconstruct the dorsal radial ligament. To our knowledge, synthetic tape augmentation for thumb CMC instability has not yet been described for this pathology. Clinical Relevance Synthetic tape augmentation for dorsal thumb CMC instability may be considered in the management of dorsal thumb CMC joint instability.
A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
Jacobson, Caron A. , Arnason, Jon , Agarwal, Shirali, Zhang, Peixin , Amber, Vian , Yared, Jean A. , Rosenthal, Allison C, Yared, Jean A , Rosenthal, Allison , Wu, Wendy

Blood Advances | July 3, 2023 | Volume: 7 | Issue: 21 | Pages: 6790-6799

10.1182/bloodadvances.2023009961 | PMID 37399456 Get It

Abstract Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in cancer immunotherapy; however, it can be associated with life-threatening neurotoxicity linked to blood-brain barrier disruption and endothelial activation. Defibrotide was shown to reduce endothelial cell activation in vitro and is approved in the United States for treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT), and in the European Union for severe VOD/SOS after HCT in patients aged >1 month. Defibrotide may stabilize the endothelium during CAR-T therapy and reduce the rate of CAR-T–associated neurotoxicity. This phase 2 study evaluated the safety and efficacy of defibrotide for prevention of CAR-T–associated neurotoxicity in patients with relapsed/refractory large B-cell lymphoma receiving axicabtagene ciloleucel. Part 1 established the recommended phase 2 dose (RP2D; 6.25 mg/kg); 20 patients (from parts 1 and 2) receiving the RP2D were evaluable for efficacy. Rate of CAR-T–associated neurotoxicity by day 30 (primary end point) was ∼50%, lower than reported in the ZUMA-1 trial (64%). Median event duration of grade ≥3 neurotoxicity was 7 days. No unexpected defibrotide-related safety findings and defibrotide-related treatment-emergent adverse events or deaths were reported. Results showed modest reduction in rate of CAR-T–associated neurotoxicity and high-grade neurotoxicity event duration relative to historical data; however, reduction was unlikely to meet the primary end point, so the study was terminated early. Nevertheless, results contribute valuable data for potential therapeutic insight on the management of CAR-T–associated neurotoxicity. This trial was registered at www.clinicaltrials.gov as #NCT03954106.
Detection of an MN1::ETV6 Gene Fusion in a Case of Acute Myeloid Leukemia with Erythroid Differentiation: A Case Report and Review of the Literature
Choate, Lauren A. , Jiang, Liuyan , Stein, Mariam I. , Shen, Wei , Peterson, Jess F , Shen, Wei , Baughn, Linda B. , Peterson, Jess F.

Case Reports in Hematology | July 3, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-6

10.1155/2023/9771388 | PMID 37434656 Get It

The MN1::ETV6 gene fusion resulting from t(12;22)(p13;q12) has been rarely reported in myeloid neoplasms. We describe a 69-year-old male with newly diagnosed acute myeloid leukemia (AML) with erythroid differentiation and t(12;22)(p13;q12) demonstrated by conventional chromosome studies. Subsequent fluorescence in situ hybridization studies demonstrated a balanced ETV6 gene rearrangement (at 12p13). To further characterize this translocation, whole-genome sequencing was performed which confirmed t(12;22) with breakpoints involving the MN1 and ETV6 genes. Herein, we describe our case and review the literature to summarize the clinical and laboratory findings in patients with this rare but recurrent MN1::ETV6 gene fusion observed in myeloid neoplasms. Importantly, this case expands the clinical spectrum associated with the MN1::ETV6 gene fusion to include AML with erythroid differentiation. Lastly, this case demonstrates the importance of moving toward more comprehensive molecular testing to fully characterize the driver events in neoplastic genomes.
Teaching NeuroImage: Olfactory Stem Cell Injection Inducing Actively Secreting Respiratory Epithelium in a Cervical Syrinx
Rotter, Juliana , Kumar, Rahul , Nesvick, Cody L. , Krauss, William E. , Tobin, W. Oliver , Tobin, W Oliver , Nesvick, Cody L , Giannini, Caterina

Neurology | July 3, 2023 | Volume: 101 | Issue: 11 | Pages: 497-498

10.1212/wnl.0000000000207463 | PMID 37400242 Get It

A Pilot Randomized Clinical Trial of Base‐in Relieving Prism Spectacle Treatment of Intermittent Exotropia
Summers, Allison I. , Morrison, David G., Chandler, Danielle L. , Henderson, Robert J. , Leske, David A. , Walker, Kimberly R., Li, Zhuokai , Melia, B. Michele, Bitner, Derek P., Kurup, Sudhi P. , Allen, Megan, Phillips, Paul H. , Nash, David L. , Grigorian, A. Paula, Kraus, Courtney L. , Miller, Aaron M. , Titelbaum, Jenna R. , Kraker, Raymond T. , Holmes, Jonathan M. , Group, for the Pediatric Eye Disease Investigator, Chen, Angela M. , Cotter, Susan A. , Group, for the Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Optometry and Vision Science | July 3, 2023 | Volume: 100 | Issue: 7 | Pages: 432-443

10.1097/opx.0000000000002039 | PMID 37399233 Get It

SIGNIFICANCE This pilot randomized trial, the first to evaluate a specific base‐in relieving prism treatment strategy for childhood intermittent exotropia, did not support proceeding to a full‐scale clinical trial. Defining and measuring prism adaptation in children with intermittent exotropia are challenging and need further study. PURPOSE This study aimed to determine whether to proceed to a full‐scale trial of relieving base‐in prism spectacles versus refractive correction alone for children with intermittent exotropia. METHODS Children 3 years old to those younger than 13 years with distance intermittent exotropia control score of ≥2 points on the Intermittent Exotropia Office Control Scale (Strabismus 2006;14:147–150; 0 [phoria] to 5 [constant]), ≥1 episode of spontaneous exotropia, and 16 to 35∆ by prism‐and‐alternate‐cover test, who did not fully prism adapt on a 30‐minute in‐office prism‐adaptation test were randomized to base‐in relieving prism (40% of the larger of distance and near exodeviations) or nonprism spectacles for 8 weeks. A priori criteria to conduct a full‐scale trial were defined for the adjusted treatment group difference in mean distance control: “proceed” (≥0.75 points favoring prism), “uncertain” (>0 to <0.75 points favoring prism), or “do not proceed” (≥0 points favoring nonprism). RESULTS Fifty‐seven children (mean age, 6.6 ± 2.2 years; mean baseline distance control, 3.5 points) received prism (n = 28) or nonprism (n = 29) spectacles. At 8 weeks, mean control values were 3.6 and 3.3 points in prism (n = 25) and nonprism (n = 25) groups, respectively, with an adjusted difference of 0.3 points (95% confidence interval, −0.5 to 1.1 points) favoring nonprism (meeting our a priori “do not proceed” criterion). CONCLUSIONS Base‐in prism spectacles, equal to 40% of the larger of the exodeviations at distance or near, worn for 8 weeks by 3‐ to 12‐year‐old children with intermittent exotropia did not yield better distance control than refractive correction alone, with the confidence interval indicating that a favorable effect of 0.75 points or larger is unlikely. There was insufficient evidence to warrant a full‐scale randomized trial.
Outcomes of Elective and Non-elective Fenestrated-branched Endovascular Aortic Repair for Treatment of Thoracoabdominal Aortic Aneurysms
Dias‐Neto, Marina , Vacirca, Andrea , Huang, Ying , Baghbani‐Oskouei, Aidin , Jakimowicz, Tomasz , Mendes, Bernardo C. , Bertoglio, Luca , Gargiulo, Mauro , Dias, Nuno , Schanzer, Andres , Gasper, Warren J. , Mani, Kevin , Timaran, Carlos H. , Schneider, Darren B. , Pedro, Luís Mendes , Tsilimparis, Nikolaos , Sweet, Matthew P. , Eagleton, Matthew J. , Khashram, Manar, Jama, Katarzyna , Panuccio, Giuseppe , Rohlffs, Fiona, Chiesa, Roberto , Kahlberg, Andrea , Schurink, Geert Willem H. , Lemmens, Charlotte , Karelis, Angelos , Parodi, Ezequiel, Habib, Mohammed , Cólon, Jesus Porras, Pavarino, Felipe, Baig, Mirza S. , Crawford, Sean A. , Garcia, Rita , Ribeiro, Tiago , Alves, Gonçalo, Gonçalves, Frederico Bastos , Kappe, Kaj O. , Knippenberg, Samira Elize Mariko van , Tran, Bich L. , Gormley, Sinead , Oderich, Gustavo S. , Baghbani, Aidin , Panuccio, Giuseppe , Dias-Neto, Marina , Schneider, Darren B , Kölbel, Tilo , Sobocinski, Jonathan , Mees, Barend M.E. , Dias, Nuno , Beck, Adam W , Farber, Mark , Haulon, Stéphan , Ferreira, Emília, Yeung, Kak Khee , Khashram, Manar , Rohlffs, Fiona , Mésnard, Thomas , Gallitto, Enrico , Faggioli, Gianluca , Gomes, Vivian Carla , Wanhainen, Anders , Habib, Mohammed, Colon, Jesus Porras, Baig, Mirza S., Melo, Ryan Gouveia e , Zettervall, Sara L , Oderich, Gustavo S.

Annals of Surgery | July 3, 2023 | Volume: 278 | Issue: 4 | Pages: 568-577

10.1097/sla.0000000000005986 | PMID 37395613 Get It

Objective: To describe outcomes after elective and non-elective fenestrated-branched endovascular aortic repair (FB-EVAR) for thoracoabdominal aortic aneurysms (TAAAs). Background: FB-EVAR has been increasingly utilized to treat TAAAs; however, outcomes after non-elective versus elective repair are not well described. Methods: Clinical data of consecutive patients undergoing FB-EVAR for TAAAs at 24 centers (2006–2021) were reviewed. Endpoints including early mortality and major adverse events (MAEs), all-cause mortality, and aortic-related mortality (ARM), were analyzed and compared in patients who had non-elective versus elective repair. Results: A total of 2603 patients (69% males; mean age 72±10 year old) underwent FB-EVAR for TAAAs. Elective repair was performed in 2187 patients (84%) and non-elective repair in 416 patients [16%; 268 (64%) symptomatic, 148 (36%) ruptured]. Non-elective FB-EVAR was associated with higher early mortality (17% vs 5%, P<0.001) and rates of MAEs (34% vs 20%, P<0.001). Median follow-up was 15 months (interquartile range, 7–37 months). Survival and cumulative incidence of ARM at 3 years were both lower for non-elective versus elective patients (50±4% vs 70±1% and 21±3% vs 7±1%, P<0.001). On multivariable analysis, non-elective repair was associated with increased risk of all-cause mortality (hazard ratio, 1.92; 95% CI] 1.50–2.44; P<0.001) and ARM (hazard ratio, 2.43; 95% CI, 1.63–3.62; P<0.001). Conclusions: Non-elective FB-EVAR of symptomatic or ruptured TAAAs is feasible, but carries higher incidence of early MAEs and increased all-cause mortality and ARM than elective repair. Long-term follow-up is warranted to justify the treatment.